Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once
weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.
Phase:
Phase 2
Details
Lead Sponsor:
NS Pharma, Inc.
Collaborators:
Cooperative International Neuromuscular Research Group Nippon Shinyaku Co Ltd Nippon Shinyaku Co., Ltd. Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS)